EGFR and neoplasm: Similarly, cetuximab, another targeted therapeutic agent that binds to the extracellular domain of EGFR and inhibits the activation of downstream signaling pathways, has demonstrated efficacy in the treatment of breast cancer by inducing apoptosis in tumor cells.